Frontiers in Pharmacology | Drugs Outcomes Research and Policies

Original Research

Accepted on 20 May 2025

Carbapenem-resistant Pseudomonas aeruginosa T3SS virulence genes and correlation between virulence and drug resistance and molecular epidemiology studies

in Drugs Outcomes Research and Policies

Jianhua Tang
Linbo Zhao
Jiekun Pu
Xuli Zhan
Qianqian Pang
Xiangyan Meng
Rui Feng
Haojun Fan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1591724

155 views

Original Research

Published on 20 May 2025

Development of a warning model for drug-induced liver injury in the older patients

in Drugs Outcomes Research and Policies

Qiaozhi Hu
Xiaoqi Li
Dan Zou
Zhiyao He
Ting Xu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1603089

462 views

Original Research

Published on 20 May 2025

Understanding community pharmacists’ intentions to report adverse drug reactions in Saudi Arabia: a theory of planned behavior analysis

in Drugs Outcomes Research and Policies

Fahad T. Alsulami
Yousef Saeed Alqarni
Wadia Saad Alruqayb
Mohammed S. Alharthi
Mohammad S. Alzahrani
Majed A. Algarni
Musaad M. Althobaiti
Saad Mohammed Almalki
Nawaf Abid Altowarqi
Hussain Ali Mathkur

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1574412

423 views

Systematic Review

Accepted on 19 May 2025

Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review

in Drugs Outcomes Research and Policies

Chang Liu
Xiaojie Liu
Ting Shi
Yun Wang
Chaoyang Sui
Wenan Zhang
Bowen Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1556705

198 views

Systematic Review

Published on 15 May 2025

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis

in Drugs Outcomes Research and Policies

Mohammad Amin Karimi
Mohammad Sadra Gholami Chahkand
Parisa Alsadat Dadkhah
Farzad Sheikhzadeh
Shayan Yaghoubi
Fatemeh Esmaeilpour Moallem
Mitra Sadat Deyhimi
Melika Arab Bafrani
Mehregan Shahrokhi
Amir Nasrollahizadeh

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1438318

1,204 views

Original Research

Accepted on 14 May 2025

Key regulatory challenges in developing modified new chemical drugs in China: A national survey study

in Drugs Outcomes Research and Policies

Lixia Fu
Guoshu Jia
Minji Wei
Yimin Cui

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1576013

105 views

Original Research

Published on 14 May 2025

Evaluation of drug interactions in outpatients taking antipsychotic medications

in Drugs Outcomes Research and Policies

Bshra A. Alsfouk
Qamar M. Aljanadi
Mona M. Almutairi

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1590167

527 views

Original Research

Published on 12 May 2025

Single-cell transcriptomics and machine learning unveil ferroptosis features in tumor-associated macrophages: Prognostic model and therapeutic strategies for lung adenocarcinoma

in Drugs Outcomes Research and Policies

Ting Ji
Juanli Jiang
Xin Wang
Kai Yang
Shaojin Wang
Bin Pan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1598756

768 views

Original Research

Published on 12 May 2025

Association of early enoxaparin prophylactic anticoagulation with ICU mortality in critically ill patients with chronic obstructive pulmonary disease: a machine learning-based retrospective cohort study

in Drugs Outcomes Research and Policies

Shan Lin
Jing Zhang
Xin Dang
Qingyuan Zhan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1588846

429 views

Systematic Review

Accepted on 08 May 2025

What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review

in Drugs Outcomes Research and Policies

Chuang Yang
Yunfei Wang
Yiyong Sun
Ying Sun
Rongyu Zhang
Chengjun Wang
Yanan Song
Wen Zhao
Jisheng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1572115

107 views

Systematic Review

Published on 02 May 2025

Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations

in Drugs Outcomes Research and Policies

Hui Zhang
Yueyun Li
Yuhang Liu
Haonan Li
Hong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1527614

1,257 views

Original Research

Published on 01 May 2025

Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop

in Drugs Outcomes Research and Policies

Ghada Mohammed Abozaid
Hussain Abdulrahman Al-Omar
Abdulaziz Alrabiah
Asma AlMuaither
Amy Jayne McKnight

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1583477

1,155 views

Original Research

Published on 01 May 2025

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for patients with unresectable hepatocellular carcinoma: a cost–utility analysis in China and the United States

in Drugs Outcomes Research and Policies

Qiuling Zhao
Yimin He
Zilin Nian
Yongjian Huang
Ruyi Huang
Lijun Lai
Lin Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1404389

797 views

Original Research

Accepted on 30 Apr 2025

Assessing the landscape of digital health implementation for data services: The Perspective of Digital Health Experts in Cameroon

in Drugs Outcomes Research and Policies

Frankline Sanyuy Nsai
Palle John Ngunde
Anna Longdoh Njunda
Tendongfor Nicholas
Cho Sabastine Anye
Juliet Nabyonga-Orem
Omer Njajou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1490778

262 views

Brief Research Report

Published on 30 Apr 2025

Regulatory challenges of digital health: the case of mental health applications and personal data in South Africa

in Drugs Outcomes Research and Policies

Marietjie Botes

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1498600

1,170 views

Original Research

Published on 29 Apr 2025

Trajectories of potentially inappropriate medication use among older adults in Saudi Arabia

in Drugs Outcomes Research and Policies

Fouad F. Jabri
Yajun Liang
Kristina Johnell
Jette Möller

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1568160

547 views